{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:10:36Z","timestamp":1788577836694,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>An easily implementable serological assay to accurately detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies is urgently needed to better track herd immunity, vaccine efficacy and vaccination rates. Herein, we report the Split-Oligonucleotide Neighboring Inhibition Assay (SONIA) which uses real-time qPCR to measure the ability of neutralizing antibodies to block binding between DNA-barcoded viral spike protein subunit 1 and the human angiotensin-converting enzyme 2 receptor protein. The SONIA neutralizing antibody assay using finger-prick dried blood spots displays 91\u201397% sensitivity and 100% specificity in comparison to the live-virus neutralization assays using matched serum specimens for multiple SARS-CoV-2 variants-of-concern. The multiplex version of this neutralizing antibody assay, using easily collectable finger-prick dried blood spots, can be a valuable tool to help reveal the impact of age, pre-existing health conditions, waning immunity, different vaccination schemes and the emergence of new variants-of-concern.<\/jats:p>","DOI":"10.1038\/s41467-022-31796-1","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T11:03:02Z","timestamp":1658401382000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Detection of neutralizing antibodies against multiple SARS-CoV-2 strains in dried blood spots using cell-free PCR"],"prefix":"10.1038","volume":"13","author":[{"given":"Kenneth","family":"Danh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna Grace","family":"Karp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malvika","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshaya","family":"Tankasala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gebhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"de Jesus Cortez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devangkumar","family":"Tandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter V.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Seftel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mars","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Bagri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7942-6746","authenticated-orcid":false,"given":"Andreas","family":"Buser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Holbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Battegay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Kate","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1025-4760","authenticated-orcid":false,"given":"John R.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dane","family":"Granger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6886-2294","authenticated-orcid":false,"given":"Elitza S.","family":"Theel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3270-4913","authenticated-orcid":false,"given":"James R.","family":"Stubbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8615-9869","authenticated-orcid":false,"given":"Laurence M.","family":"Corash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8718-8821","authenticated-orcid":false,"given":"Cheng-ting","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"key":"31796_CR1","doi-asserted-by":"publisher","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","volume":"55","author":"CC Lai","year":"2020","unstructured":"Lai, C. C., Shih, T. P., Ko, W. C., Tang, H. J. & Hsueh, P. R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J. Antimicrob. Agents 55, 105924 (2020).","journal-title":"Int J. Antimicrob. Agents"},{"key":"31796_CR2","doi-asserted-by":"publisher","unstructured":"Tang, Y. W., Schmitz, J. E., Persing, D. H. & Stratton, C. W. The Laboratory Diagnosis of COVID-19 Infection: Current Issues and Challenges. J Clin Microbiol, https:\/\/doi.org\/10.1128\/JCM.00512-20 (2020).","DOI":"10.1128\/JCM.00512-20"},{"key":"31796_CR3","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1172\/JCI138003","volume":"130","author":"A Casadevall","year":"2020","unstructured":"Casadevall, A. & Pirofski, L. A. The convalescent sera option for containing COVID-19. J. Clin. Invest. 130, 1545\u20131548 (2020).","journal-title":"J. Clin. Invest."},{"key":"31796_CR4","unstructured":"Duan, K. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl Acad. Sci. USA. pii: 202004168 (2020)."},{"key":"31796_CR5","doi-asserted-by":"publisher","unstructured":"Ju, B. et al. Potent human neutralizing antibodies elicited by SARS-CoV-2 infection. bioRxiv https:\/\/doi.org\/10.1101\/2020.03.21.990770 (2020).","DOI":"10.1101\/2020.03.21.990770"},{"key":"31796_CR6","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/22221751.2020.1743767","volume":"9","author":"J Nie","year":"2020","unstructured":"Nie, J. et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg. Microbes Infect. 9, 680\u2013686 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"31796_CR7","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41586-021-04005-0","volume":"600","author":"F Schmidt","year":"2021","unstructured":"Schmidt, F. et al. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. Nature 600, 512\u2013516 (2021).","journal-title":"Nature"},{"key":"31796_CR8","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","volume":"38","author":"CW Tan","year":"2020","unstructured":"Tan, C. W. et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat. Biotechnol. 38, 1073\u20131078 (2020).","journal-title":"Nat. Biotechnol."},{"key":"31796_CR9","doi-asserted-by":"publisher","first-page":"e0123121","DOI":"10.1128\/JCM.01231-21","volume":"59","author":"ES Theel","year":"2021","unstructured":"Theel, E. S. et al. SARS-CoV-2 serological assays dependent on dual-antigen Binding demonstrate diverging kinetics relative to other antibody detection methods. J. Clin. Microbiol. 59, e0123121 (2021).","journal-title":"J. Clin. Microbiol."},{"key":"31796_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1021\/acscentsci.5b00340","volume":"2","author":"C Tsai","year":"2016","unstructured":"Tsai, C. et al. Ultrasensitive antibody detection by agglutination-PCR (ADAP). ACS Cent. Sci. 2, 139\u2013147 (2016).","journal-title":"ACS Cent. Sci."},{"key":"31796_CR11","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.jaci.2017.11.021","volume":"141","author":"C Tsai","year":"2018","unstructured":"Tsai, C. et al. Isotype-specific agglutination-PCR (ISAP): A sensitive and multiplex method for measuring allergen-specific IgE. J. Allergy Clin. Immunol. 141, 1901\u20131904 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"31796_CR12","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1073\/pnas.1711004115","volume":"115","author":"C Tsai","year":"2018","unstructured":"Tsai, C. et al. Antibody detection by agglutination\u2013PCR (ADAP) enables early diagnosis of HIV infection by oral fluid analysis. Proc. Natl Acad. Sci. USA 115, 1250\u20131255 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"31796_CR13","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1537-2995.2007.01594.x","volume":"48","author":"P Schlenke","year":"2008","unstructured":"Schlenke, P. et al. Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers. Transfusion 48, 697\u2013705 (2008).","journal-title":"Transfusion"},{"key":"31796_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/jca.21482","volume":"32","author":"JF Brown","year":"2017","unstructured":"Brown, J. F. et al. Apheresis for collection of Ebola convalescent plasma in Liberia. J. Clin. Apher. 32, 175\u2013181 (2017).","journal-title":"J. Clin. Apher."},{"key":"31796_CR15","doi-asserted-by":"publisher","unstructured":"Ng, D. et al. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area. MedRxiv https:\/\/doi.org\/10.1101\/2020.05.19.20107482 (2020).","DOI":"10.1101\/2020.05.19.20107482"},{"key":"31796_CR16","doi-asserted-by":"publisher","unstructured":"Bar-On, Y. M. et al. BNT162b2 vaccine booster dose protection: A nationwide study from Israel. MedRxiv https:\/\/doi.org\/10.1101\/2021.08.27.21262679 (2021).","DOI":"10.1101\/2021.08.27.21262679"},{"key":"31796_CR17","first-page":"pii:e02002","volume":"92","author":"L Wang","year":"2018","unstructured":"Wang, L. et al. Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on the Middle East respiratory syndrome coronavirus spike glycoprotein to avoid neutralization escape. J. Virol. 92, pii:e02002\u2013e02017 (2018).","journal-title":"J. Virol."},{"key":"31796_CR18","first-page":"30014","volume":"pii:S0887-7963","author":"L Chang","year":"2020","unstructured":"Chang, L. et al. Coronavirus disease 2019: coronaviruses and blood safety. Transfus. Med Rev. pii:S0887-7963, 30014\u201330016 (2020).","journal-title":"Transfus. Med Rev."},{"key":"31796_CR19","doi-asserted-by":"publisher","unstructured":"Dean, C. L. et al. Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States. Transfusion. https:\/\/doi.org\/10.1111\/trf.15739 (2020).","DOI":"10.1111\/trf.15739"},{"key":"31796_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-76913-6","volume":"10","author":"DG Karp","year":"2020","unstructured":"Karp, D. G. et al. A serological assay to detect SARS-CoV-2 antibodies in at-home collected finger-prick dried blood spots. Sci. Rep. 10, 20188 (2020).","journal-title":"Sci. Rep."},{"key":"31796_CR21","doi-asserted-by":"publisher","unstructured":"Wu, F. et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. meRxiv https:\/\/doi.org\/10.1101\/2020.03.30.20047365.","DOI":"10.1101\/2020.03.30.20047365"},{"key":"31796_CR22","doi-asserted-by":"crossref","unstructured":"Fenwick, C. et al. A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma. Sci Transl Med. 13 (2021).","DOI":"10.1126\/scitranslmed.abi8452"},{"key":"31796_CR23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fmicb.2017.00108","volume":"8","author":"P Kralik","year":"2017","unstructured":"Kralik, P. & Ricchi, M. A Basic Guide To Real Time PCR in microbial diagnostics: definitions, parameters, and everything. Front. Microbiol. 8, 108 (2017).","journal-title":"Front. Microbiol."},{"key":"31796_CR24","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1001\/jama.2021.4388","volume":"325","author":"VV Edara","year":"2021","unstructured":"Edara, V. V., Hudson, W. H., Xie, X., Ahmed, R. & Suthar, M. S. Neutralizing antibodies against SARS-CoV-2 variants after infection and vaccination. JAMA 325, 1896\u20131898 (2021).","journal-title":"JAMA"},{"key":"31796_CR25","doi-asserted-by":"publisher","first-page":"e143213","DOI":"10.1172\/jci.insight.143213","volume":"5","author":"C Zeng","year":"2020","unstructured":"Zeng, C. et al. Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors. JCI Insight 5, e143213 (2020).","journal-title":"JCI Insight"},{"key":"31796_CR26","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"31796_CR27","doi-asserted-by":"crossref","unstructured":"Sancilio, A. E. et al. A surrogate virus neutralization test to quantify antibody-mediated inhibition of SARS-CoV-2 in finger stick dried blood spot samples. Sci. Rep. 11: 15321 (2021).","DOI":"10.1038\/s41598-021-94653-z"},{"key":"31796_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22958-8","volume":"12","author":"S Dispinseri","year":"2021","unstructured":"Dispinseri, S. et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nat. Commun. 12, 2670 (2021).","journal-title":"Nat. Commun."},{"key":"31796_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2020-136180","volume":"136","author":"N Khanna","year":"2020","unstructured":"Khanna, N. et al. Efficacy of COVID-19 pathogen inactivated convalescent plasma for patients with moderate to severe acute COVID-19: A case matched control study. Blood 136, 29\u201330 (2020).","journal-title":"Blood"},{"key":"31796_CR30","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrap","year":"2020","unstructured":"Wrap, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"31796_CR31","doi-asserted-by":"publisher","unstructured":"Okba, N. M. A. et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients. Emerg Infect Dis. 26. https:\/\/doi.org\/10.3201\/eid2607.200841 (2020).","DOI":"10.3201\/eid2607.200841"},{"key":"31796_CR32","doi-asserted-by":"publisher","unstructured":"Servellita, V. et al. Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta 2 variants. MedRxiv https:\/\/doi.org\/10.1101\/2022.01.25.22269794 (2022).","DOI":"10.1101\/2022.01.25.22269794"},{"key":"31796_CR33","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nbt0502-473","volume":"20","author":"S Fredriksson","year":"2002","unstructured":"Fredriksson, S. et al. Protein detection using proximity-dependent DNA ligation assays. Nat. Biotechnol. 20, 473\u2013477 (2002).","journal-title":"Nat. Biotechnol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31796-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31796-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31796-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T13:17:33Z","timestamp":1669295853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31796-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["31796"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-31796-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.05.28.20105692","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]},"assertion":[{"value":"31 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.D., D.K., M.S., A.T., D.T., F.J.C., D.G., P.V.R., D.S., and C.T.T. were employed by Enable Biosciences. F.J.C., D.G., K.D., D.T., P.V.R., D.S., and C.T.T. are shareholders of Enable Biosciences. P.V.R. and C.T.T. are inventors of the ADAP patent US11149296B2 licensed from the University of California, Berkeley to Enable Biosciences. The ADAP and SONIA assay used in this study is a product in development. This does not alter our adherence to journal policies on sharing data and materials. A.B. and L.M.C. were employees and shareholders of Cerus Corporation, a manufacturer of a convalescent plasma inactivation system. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4212"}}